Tonix Pharmaceuticals to Present at Guggenheim Healthcare Innovation Conference, Spotlighting Commercial-Stage CNS and Immunology Strategy

Tonix Pharmaceuticals' upcoming presentation at the Guggenheim Healthcare Innovation Conference highlights its commercial-stage portfolio, including the first new fibromyalgia treatment in over 15 years, and its broader CNS and immunology pipeline.

Chicago Metrowire Staff
••Healthcare
Tonix Pharmaceuticals to Present at Guggenheim Healthcare Innovation Conference, Spotlighting Commercial-Stage CNS and Immunology Strategy

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, will present and host one-on-one meetings at Guggenheim’s 3rd Annual Healthcare Innovation Conference in Boston on Nov. 10, 2026. President and CEO Seth Lederman, M.D., will deliver the company presentation from 4 to 4:25 p.m. ET. A live webcast and replay will be available under the News & Events tab in the Investors section of the company’s website.

The presentation matters because it gives Tonix a high-visibility forum to frame its transition from a clinical-stage developer to a commercial operator with multiple approved products and a pipeline aimed at high-unmet-need areas of central nervous system (CNS) and immunology. The company’s flagship medicine, TONMYA(TM) (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in more than 15 years, a milestone that positions Tonix to compete in a market that has seen little innovation. Tonix’s CNS commercial infrastructure supports its marketed products, including acute migraine therapies Zembrace(R) SymTouch(R) and Tosymra(R), giving the company a revenue-generating base to fund further development.

Beyond its commercial portfolio, Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. The company’s CNS portfolio also includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These programs are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Investors and industry observers will be watching the Guggenheim conference for signals on how Tonix plans to scale its commercial infrastructure, allocate capital across its CNS and immunology programs, and differentiate TONMYA in a therapeutic area long dominated by older therapies. The event also offers a window into management’s priorities as the company balances near-term product launches with longer-term pipeline bets. For those tracking the company, the latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP, and the full press release can be viewed at https://ibn.fm/f7udM.

The announcement was distributed through InvestorWire, a specialized communications platform focused on wire-grade press release syndication. InvestorWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, offering services that include editorial syndication to 5,000+ outlets and social media distribution to millions of followers.

Blockchain Registration

QR Code for Blockchain Registration